GITR-Binding Antibodies for Selective T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for targeting diseases like cancer lack effective methods to modulate glucocorticoid-induced TNFR-related protein (GITR) activity, which is crucial for enhancing immune responses, particularly T cell responses.
Innovation Solution
Development of isolated human monoclonal antibodies that specifically bind to GITR, stimulating antigen-specific T cell responses, activating T cells, and inhibiting the binding of GITR ligand, thereby promoting anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional strategies are used for targeting diseases like cancer, then current treatment methods are applied, but effective modulation of GITR activity to enhance immune responses is lacking
Solution Approach 1:
The patent applies parameter changes by developing monoclonal antibodies with specific binding affinities to GITR that can modulate its activity. The antibodies are engineered to bind to GITR with controlled affinity parameters, enabling effective immune response modulation without requiring complex alternative approaches. This resolves the contradiction by changing the binding parameters of the antibody-GITR interaction to achieve reliable immune enhancement.
2Reliability
If GITR engagement is promoted to enhance T cell activation and proliferation, then anti-tumor immunity is improved, but regulatory T cell suppression function may be affected
Solution Approach 1:
The patent applies local quality by designing antibodies that selectively engage GITR on specific T cell populations (effector T cells) while having differential effects on regulatory T cells. The monoclonal antibodies are engineered to bind GITR with properties that promote effector T cell activation and proliferation while simultaneously reducing regulatory T cell suppressive function. This localized differential effect resolves the contradiction by applying GITR engagement selectively to achieve anti-tumor immunity while mitigating harmful suppression.
3Reliability
If monoclonal antibodies are developed to specifically bind GITR, then antigen-specific T cell responses are stimulated, but complexity of antibody development and characterization increases
Solution Approach 1:
The patent applies copying by using established monoclonal antibody development methodologies and characterization protocols to create GITR-specific antibodies. Rather than developing entirely new complex systems, the invention leverages proven techniques for generating and validating monoclonal antibodies, adapting them to the GITR target. This approach achieves high specificity in T cell response stimulation while managing development complexity through replication of successful existing methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively stimulate antigen-specific T cell responses, enhance cytokine production, and activate T cells, leading to increased anti-tumor immune responses and potential cancer treatment options.
Implementation Method 1
isolated antibodies, such as monoclonal antibodies, in particular human monoclonal antibodies, that specifically bind GITR
Data Source
AI summary
Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.